Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obecabtagene Autoleucel Consolidation in Adult Patients With Acute Lymphoblastic Leukemia in First Complete Remission Without Measurable Residual Disease
NCT07400029Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of obecabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07400029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400029.